Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223596 | 0.87 | NR4A2 (0.61) | NR4A2CREBBPNPC1PDE1C | |
| SCHEMBL29886596 | 0.87 | NR4A2 (0.61) | NR4A2CREBBPNPC1PDE1C | |
| SCHEMBL18837110 | 0.84 | NR4A2 (0.51) | NR4A2CREBBPNPC1GPR84CTNNB1 | |
| SCHEMBL26250363 | 0.83 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1RAB9APDE1C | |
| SCHEMBL9937058 | 0.83 | NR4A2 (1.00) | NR4A2CREBBPGPR84MAP2K1RAB9A | |
| SCHEMBL2035795 | 0.83 | NR4A2 (0.68) | NR4A2CREBBPGPR84MAP2K1 | |
| SCHEMBL5329797 | 0.83 | NR4A2 (0.68) | NR4A2CREBBPNPC1CTNNB1WNT3A | |
| SCHEMBL3554889 | 0.83 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1RAB9A | |
| SCHEMBL3995494 | 0.81 | GPR84 (0.51) | NR4A2NPC1GPR84CTNNB1WNT3A | |
| SCHEMBL15356576 | 0.81 | PBRM1 (0.56) | NR4A2CREBBPNPC1GPR84CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885NPC1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.